(Reuters) -Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's ...
(Reuters) -Novo Nordisk said on Friday a late-stage trial with a high-dose version of the active ingredient semaglutide, used in its blockbuster obesity drug Wegovy, helped overweight patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback